XML 60 R45.htm IDEA: XBRL DOCUMENT v3.24.0.1
Collaborative Agreements (Details)
 1 Months Ended 12 Months Ended
Jun. 10, 2022
USD ($)
Aug. 05, 2019
USD ($)
shares
Jun. 30, 2019
USD ($)
shares
Sep. 30, 2018
USD ($)
Dec. 31, 2017
USD ($)
Sep. 25, 2017
USD ($)
Aug. 15, 2017
USD ($)
Aug. 31, 2016
USD ($)
Aug. 31, 2016
TWD ($)
Jul. 27, 2016
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
$ / shares
shares
Dec. 31, 2021
Dec. 31, 2018
USD ($)
Dec. 31, 2015
USD ($)
Dec. 31, 2015
TWD ($)
Jul. 01, 2022
Dec. 24, 2018
USD ($)
$ / shares
shares
Dec. 24, 2018
$ / shares
Collaborative Agreements [Line Items]                                        
Milestone payments royalty percentage                       12.00%                
Collaboration revenue                                 $ 50,000,000      
Cash equivalent                     $ 1,600,000 $ 100,000,000       $ 1,600,000        
Percentage of net sales                       5.00%                
Agreement percentage                       15.00% 10.00% 5.00%            
Outstanding amount (in Shares) | shares                         5,000,000              
Value of new shares issued [1]                       $ 7,940 $ 3,286              
Common stock per share price | (per share)                       $ 0.001 $ 0.001           $ 1.6 $ 50
Equity method long term investment (in Shares) | shares                                     1,530,000  
Recognized investment loss                       $ (7,446)   $ 549          
Service agreement eligibility amount $ 3,000,000                                      
Milestone regulatory payment amount period 3 years                                      
Loan amount                       $ 1,000,000                
Percentage of working capital convertible loan                       5.00%                
Conversion of shares, description                       The Company may convert the Note at any time into shares of Rgene’s common stock at either (i) a fixed conversion price equal to $1.00 per share or (ii) 20% discount of the stock price of the then most recent offering, whichever is lower; the conversion price is subject to adjustment as set forth in the Note.                
Rgene Corporation [Member]                                        
Collaborative Agreements [Line Items]                                        
Ownership percentage                       26.65% 26.65%              
Ownership percentage                                   12.80%    
BHK Co-Development Agreement [Member]                                        
Collaborative Agreements [Line Items]                                        
Milestone payment                 $ 31,649,000 $ 10,000,000                    
Description of payment settlement                       ●Upon the signing of the BHK Co-Development Agreement: $1 million, or 10% of total payment   ● Upon the first Investigational New Drug (IND) submission and BioLite Taiwan will deliver all data to BHK according to FDA Reviewing requirement: $1 million, or 10% of total payment   ● At the completion of first phase II clinical trial: $1 million, or 10% of total payment   ● At the initiation of phase III of clinical trial research: $3 million, or 30% of total payment   ● Upon the New Drug Application (NDA) submission: $4 million, or 40% of total payment                
Upfront cash payment                     $ 1,000,000         1,000,000        
Data and development percentage                     10.00%                  
Total cash amount               $ 1,000,000     $ 10,000,000                  
Co-Dev Agreement [Member]                                        
Collaborative Agreements [Line Items]                                        
Data and development percentage                       50.00%                
Cash amount             $ 3,000,000                          
Addition cash payment                       $ 3,000,000                
Additional paid-in capital         $ 3,000,000                              
Cash received         450,000                              
Co-Dev Agreement [Member] | Rgene Corporation [Member]                                        
Collaborative Agreements [Line Items]                                        
Ownership percentage                       6.40%                
Rgene Corporation [Member]                                        
Collaborative Agreements [Line Items]                                        
Value of new shares issued                                     $ 2,550,000  
Collaborative Agreement [Member]                                        
Collaborative Agreements [Line Items]                                        
Data and development percentage                       50.00%                
Total cash amount       $ 3,000,000                                
Cash amount                       $ 3,000,000                
Licensing rights           $ 3,000,000                            
Research and development expense         $ 3,000,000                              
BioFirst Corporation Purchase Agreement [Member]                                        
Collaborative Agreements [Line Items]                                        
Shares issued (in Shares) | shares   414,702 428,571                                  
Common stock consideration   $ 2,902,911 $ 3,000,000                                  
Service Agreements [Member] | Rgene Corporation [Member]                                        
Collaborative Agreements [Line Items]                                        
Ownership percentage                       31.62%                
BioLite Taiwan [Member]                                        
Collaborative Agreements [Line Items]                                        
Collaboration revenue                               50,000,000        
Cash equivalent                     $ 1,600,000         $ 1,600,000        
Outstanding amount (in Shares) | shares                         5,000,000              
[1] Prior period results have been adjusted to reflect the 1-for-10 reverse stock split effected on July 25, 2023.